[Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience
[Display omitted] Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoria...
Saved in:
| Published in | Actas dermo-sifiliográficas Vol. 113; no. 4; pp. T401 - T406 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Spain
Elsevier España, S.L.U
01.04.2022
Elsevier |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0001-7310 1578-2190 |
| DOI | 10.1016/j.ad.2021.05.027 |
Cover
| Abstract | [Display omitted]
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs.
El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaban en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por eventos adversos. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos. |
|---|---|
| AbstractList | [Display omitted]
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs.
El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaban en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por eventos adversos. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos. Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs. Resumen: El comienzo de la psoriasis en la edad pediátrica, aunque generalmente leve, puede requerir tratamiento sistémico en las formas moderadas o graves de la enfermedad. El objetivo de este trabajo es analizar la frecuencia relativa, las características de los pacientes, el tratamiento empleado y los eventos adversos observados a partir del registro BIOBADADERM en niños y jóvenes con psoriasis moderada-grave. Del total de 3.946 pacientes del registro, se incluyen 24 pacientes menores de 21 años, con una edad media al inicio del tratamiento en BIOBADADERM de 16,1 años y un PASI medio de 9,4. El 67% de los pacientes estaban en tratamiento sistémico clásico al inicio del registro. Catorce pacientes (58%) suspendieron el tratamiento por pérdida o falta de eficacia o por eventos adversos. En conclusión, los datos del registro BIOBADADERM muestran que los menores representan un grupo muy pequeño dentro de los pacientes con psoriasis que reciben tratamiento sistémico y son manejados más frecuentemente con tratamientos clásicos. Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments used, and adverse events. Of the 3946 patients in the registry, 24 were aged 21 years or younger. The mean age of this group when they started treatment upon registration on Biobadaderm was 16.1 years and the mean Psoriasis Area and Severity Index was 9.4. In 67% the first treatment recorded was with a conventional systemic drug. Treatment was discontinued in 14 patients (58%) due to adverse events or a loss or lack of effectiveness. In conclusion, the BIOBADADERM registry shows that young people account for a small proportion of psoriasis patients receiving systemic treatment, and they are more likely to be treated using conventional systemic drugs. Graphical abstract |
| Author | Rodríguez, L. Lopez-Estebaranz, J.L. García-Donoso, C. Velasco, L.-M. García-Doval, I. Daudén, E. Gómez-García, F.J. Belinchón, I. Baniandrés-Rodríguez, O. Herrera-Acosta, E. de la Cueva, P. Mateu, A. Nieto Benito, L.M. Carrascosa, J.M. Carretero, G. Riera-Monroig, J. Ruiz-Genao, D.P. Botella-Estrada, R. Ferrán, M. Descalzo, M.A. Herrera-Ceballos, E. Rivera-Díaz, R. Sahuquillo-Torralba, A. Ballescá, F. Vilar-Alejo, J. |
| Author_xml | – sequence: 1 givenname: L.M. surname: Nieto Benito fullname: Nieto Benito, L.M. email: lula.m.nieto@gmail.com organization: Departamento de Dermatología, CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain – sequence: 2 givenname: G. surname: Carretero fullname: Carretero, G. organization: Departamento de Dermatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain – sequence: 3 givenname: R. surname: Rivera-Díaz fullname: Rivera-Díaz, R. organization: Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain – sequence: 4 givenname: J.M. surname: Carrascosa fullname: Carrascosa, J.M. organization: Departamento de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain – sequence: 5 givenname: E. surname: Daudén fullname: Daudén, E. organization: Departamento de Dermatología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain – sequence: 6 givenname: P. surname: de la Cueva fullname: de la Cueva, P. organization: Departamento de Dermatología, Hospital Universitario Infanta Leonor, Madrid, Spain – sequence: 7 givenname: A. surname: Sahuquillo-Torralba fullname: Sahuquillo-Torralba, A. organization: Departamento de Dermatología, Hospital Universitario y Politécnico La Fe, Instituto de investigación Sanitaria La Fe (IIS La Fe), Facultad de Medicina, Universidad de Valencia, Valencia, Spain – sequence: 8 givenname: E. surname: Herrera-Acosta fullname: Herrera-Acosta, E. organization: Departamento de Dermatología, Hospital Universitario Virgen de la Victoria, Málaga, Spain – sequence: 9 givenname: O. surname: Baniandrés-Rodríguez fullname: Baniandrés-Rodríguez, O. organization: Departamento de Dermatología, CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain – sequence: 10 givenname: J.L. surname: Lopez-Estebaranz fullname: Lopez-Estebaranz, J.L. organization: Departamento de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain – sequence: 11 givenname: I. surname: Belinchón fullname: Belinchón, I. organization: Departamento de Dermatología, Hospital General Universitario de Alicante-ISABIAL-UMH, Alicante, Spain – sequence: 12 givenname: J. surname: Riera-Monroig fullname: Riera-Monroig, J. organization: Departamento de Dermatología, Hospital Clinic de Barcelona, UB, Barcelona, Spain – sequence: 13 givenname: M. surname: Ferrán fullname: Ferrán, M. organization: Departamento de Dermatología, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain – sequence: 14 givenname: F.J. surname: Gómez-García fullname: Gómez-García, F.J. organization: Departamento de Dermatología, Hospital Universitario Reina Sofía, Córdoba, Spain – sequence: 15 givenname: A. surname: Mateu fullname: Mateu, A. organization: Departamento de Dermatología, Hospital Universitario Doctor Peset, Valencia, Spain – sequence: 16 givenname: L. surname: Rodríguez fullname: Rodríguez, L. organization: Departamento de Dermatología, Hospital Virgen del Rocío, Sevilla, Spain – sequence: 17 givenname: J. surname: Vilar-Alejo fullname: Vilar-Alejo, J. organization: Departamento de Dermatología, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain – sequence: 18 givenname: C. surname: García-Donoso fullname: García-Donoso, C. organization: Departamento de Dermatología, Hospital Universitario 12 de Octubre, Madrid, Spain – sequence: 19 givenname: F. surname: Ballescá fullname: Ballescá, F. organization: Departamento de Dermatología, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain – sequence: 20 givenname: L.-M. surname: Velasco fullname: Velasco, L.-M. organization: Departamento de Dermatología, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain – sequence: 21 givenname: R. surname: Botella-Estrada fullname: Botella-Estrada, R. organization: Departamento de Dermatología, Hospital Universitario y Politécnico La Fe, Instituto de investigación Sanitaria La Fe (IIS La Fe), Facultad de Medicina, Universidad de Valencia, Valencia, Spain – sequence: 22 givenname: E. surname: Herrera-Ceballos fullname: Herrera-Ceballos, E. organization: Departamento de Dermatología, Hospital Universitario Virgen de la Victoria, Málaga, Spain – sequence: 23 givenname: D.P. surname: Ruiz-Genao fullname: Ruiz-Genao, D.P. organization: Departamento de Dermatología, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain – sequence: 24 givenname: M.A. surname: Descalzo fullname: Descalzo, M.A. organization: Unidad de Investigación, Fundación Piel Sana, AEDV, Madrid, Spain – sequence: 25 givenname: I. surname: García-Doval fullname: García-Doval, I. organization: Unidad de Investigación, Fundación Piel Sana, AEDV, Madrid, Spain |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35477588$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kkFrGzEQhZeS0jhp7z0V_QG7ktZaaXMoOInbGBJiEvdQShFazdiVu1kZSTb1v48cpzkE6pNgeO8T896cFEed77AoPjI6YJRVn5cDAwNOORtQMaBcvil6TEjV56ymR0WPUsr6smT0uDiJcUkpFyWt3hXHpRhKKZTqFZufs2C62JqEQExIzrb4i9x4wJBHJHlyjxsMSKbRB2eii8R1ZIrgTArOEtMB-eHX3YJMTXLYpXhGZr-RnE9uz0eXo8vx3Q25w4WLKWzJ-O8KQxZZfF-8nZs24ofn97T4_nU8u7jqX99-m1yMrvt2KOrURwDGFYiKs1IOS5gbW86VtE1dqbnCuuKSWQRRN1AaAVY2RlmsLaCoa-BNeVpM9lzwZqlXwT2YsNXeOP008GGhn5fWRjQKKsbrEumwEaAUUNUoQYFLlYmZ9WnPWq2bB4QX2r8ws4DuBTb4GAPOXySM6l1feqkN6F1fmgqd-8qW6pXFupSD9F0KxrWHjGd7I-b0Ng6DjvYpWXABbcrruUPmL6_MtnWds6b9g1uMS78OXW5FMx25pvp-d0e7M-I8nxCVLAPU_wGH_34EUSbVzA |
| CitedBy_id | crossref_primary_10_1016_j_ad_2023_04_027 crossref_primary_10_1016_j_ad_2023_02_017 |
| Cites_doi | 10.1016/j.jaad.2020.07.087 10.1111/pde.12782 10.1111/bjd.19147 10.1016/S0140-6736(17)31189-3 10.1111/bjd.14326 10.1016/j.ad.2018.05.003 10.1016/j.jaad.2019.08.049 10.1001/jamadermatol.2017.3029 10.3109/09546634.2015.1120852 10.1111/jdv.17002 10.1016/j.jaad.2019.08.019 10.1016/j.jaad.2015.09.056 10.1016/j.ad.2020.05.008 10.12788/cutis.0115 10.1016/j.ad.2010.10.016 10.1080/09546634.2018.1476655 10.1111/bjd.19018 10.1016/j.jaad.2018.06.056 |
| ContentType | Journal Article |
| Copyright | 2021 AEDV AEDV Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved. |
| Copyright_xml | – notice: 2021 AEDV – notice: AEDV – notice: Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved. |
| CorporateAuthor | the BIOBADADERM study group BIOBADADERM study group |
| CorporateAuthor_xml | – name: the BIOBADADERM study group – name: BIOBADADERM study group |
| DBID | 6I. AAFTH AAYXX CITATION NPM DOA |
| DOI | 10.1016/j.ad.2021.05.027 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed |
| DatabaseTitleList | PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM |
| EISSN | 1578-2190 |
| EndPage | T406 |
| ExternalDocumentID | oai_doaj_org_article_a5b8d61293e04b5d88d08b850d278cde 35477588 10_1016_j_ad_2021_05_027 S0001731022002071 1_s2_0_S0001731022002071 |
| Genre | Case Reports |
| GroupedDBID | 0R~ 4.4 457 53G 65R AAEDT AAEDW AALRI AAXUO AAYWO ABJNI ACRLP ACVFH ADBBV ADCNI ADCUG ADVLN AEIPS AEUPX AEVXI AFPUW AFTJW AIGII AIKHN AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ASPBG AVWKF AZFZN BAWUL EBS EJD F5P FDB FGOYB FIRID GROUPED_DOAJ HZ~ O9- OK1 P-8 P-9 P2P R2- SES Z7D AACTN AFRHN AFXIZ BNPGV DIK RIG SSH 6I. AAFTH NCXOZ AAYXX CITATION --K --M .~1 1B1 1P~ 1~. 1~5 5VS 7-5 71M 8P~ AAIKJ AAKOC AAOAW AAQFI AAXKI ABBQC ABMAC ABMZM ABWVN ABXDB ACDAQ ACGFS ACIEU ACRPL ADEZE ADNMO AEBSH AEKER AGCQF AGHFR AGRNS AGUBO AGYEJ AIEXJ AJRQY ANZVX AXJTR BKOJK BLXMC EFJIC EFKBS EP3 FEDTE FNPLU FYGXN GBLVA HVGLF J1W KOM M41 MO0 N9A NPM O-L OAUVE OB. OM~ OZT PC. Q38 ROL SDF SPCBC SSZ T5K ~G- |
| ID | FETCH-LOGICAL-c459t-edd128d56213743dfac3f87cb968f8e96271ced59bd3a5dc7ba8ce9cde599d2b3 |
| IEDL.DBID | AIKHN |
| ISSN | 0001-7310 |
| IngestDate | Wed Aug 27 01:26:23 EDT 2025 Mon Jul 21 06:02:36 EDT 2025 Thu Sep 18 00:26:23 EDT 2025 Thu Apr 24 22:55:34 EDT 2025 Thu Jul 20 20:12:26 EDT 2023 Tue Feb 25 19:56:09 EST 2025 Tue Aug 26 16:32:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Registries Registros Psoriasis BIOBADADERM Infancia Childhood |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2021 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c459t-edd128d56213743dfac3f87cb968f8e96271ced59bd3a5dc7ba8ce9cde599d2b3 |
| OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0001731022002071 |
| PMID | 35477588 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a5b8d61293e04b5d88d08b850d278cde pubmed_primary_35477588 crossref_primary_10_1016_j_ad_2021_05_027 crossref_citationtrail_10_1016_j_ad_2021_05_027 elsevier_sciencedirect_doi_10_1016_j_ad_2021_05_027 elsevier_clinicalkeyesjournals_1_s2_0_S0001731022002071 elsevier_clinicalkey_doi_10_1016_j_ad_2021_05_027 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-04-01 |
| PublicationDateYYYYMMDD | 2022-04-01 |
| PublicationDate_xml | – month: 04 year: 2022 text: 2022-04-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Spain |
| PublicationPlace_xml | – name: Spain |
| PublicationTitle | Actas dermo-sifiliográficas |
| PublicationTitleAlternate | Actas Dermosifiliogr |
| PublicationYear | 2022 |
| Publisher | Elsevier España, S.L.U Elsevier |
| Publisher_xml | – name: Elsevier España, S.L.U – name: Elsevier |
| References | Bodemer, Kaszuba, Kingo, Tsianakas, Morita, Rivas (bib0170) 2021; 35 Philipp, Menter, Nikkels, Barber, Landells, Eichenfield (bib0165) 2020; 183 Kaushik, Lebwohl (bib0105) 2019; 80 Ollech, Zvulunov, Pavlovsky, Hodak, Ben-Amitai (bib0120) 2019; 30 Menter, Cordoro, Davis, Kroshinsky, Paller, Armsrong (bib0110) 2020; 82 European Medicines Agency. Available from Bronckers, Seyger, West, Lara-Corrales, Tollefson, Tom (bib0140) 2017; 153 [accessed 7.2.21]. Ruiz-Genao, Carretero, Rivera, Ferrándiz, Daudén, de la Cueva (bib0130) 2020; 111 Rivera, García-Doval, Carretero, Daudén, Sánchez-Carazo, Ferrándiz (bib0125) 2011; 102 Garber, Creighton-Smith, Sorensen, Dumont, Gottlieb (bib0185) 2015; 14 Paller, Siegfried, Pariser, Rice, Trivedi, Iles (bib0155) 2016; 74 Papp, Thaçi, Marcoux, Weibel, Philipp, Ghislain (bib0160) 2017; 390 Batalla, Fernández-Torres, Rodríguez-Pazos, Monteagudo, Pardavila-Riveiro, Rodríguez-Lojo (bib0200) 2018; 109 Paller, Seyger, Alejandro Magariños, Bagel, Pinter, Cather (bib0175) 2020; 183 Pithadia, Reynolds, Lee, Wu (bib0135) 2020; 106 Di Lernia, Stingeni, Boccaletti, Calzavara Pinton, Guarneri, Belloni Fortina (bib0145) 2016; 27 Paller, Hong, Becker, de Lucas, Paris, Zhang (bib0150) 2020; 82 Klufas, Wald, Strober (bib0195) 2016; 33 Elmets, Korman, Prater, Wong, Rupani, Kivelevitch (bib0115) 2021; 84 Charbit, Mahé, Pahn, Chiaverini, Boralevi, Bourrat (bib0190) 2015; 174 Rivera (10.1016/j.ad.2021.05.027_bib0125) 2011; 102 Pithadia (10.1016/j.ad.2021.05.027_bib0135) 2020; 106 Bodemer (10.1016/j.ad.2021.05.027_bib0170) 2021; 35 Garber (10.1016/j.ad.2021.05.027_bib0185) 2015; 14 Menter (10.1016/j.ad.2021.05.027_bib0110) 2020; 82 Papp (10.1016/j.ad.2021.05.027_bib0160) 2017; 390 Batalla (10.1016/j.ad.2021.05.027_bib0200) 2018; 109 Charbit (10.1016/j.ad.2021.05.027_bib0190) 2015; 174 Elmets (10.1016/j.ad.2021.05.027_bib0115) 2021; 84 Ruiz-Genao (10.1016/j.ad.2021.05.027_bib0130) 2020; 111 Di Lernia (10.1016/j.ad.2021.05.027_bib0145) 2016; 27 Paller (10.1016/j.ad.2021.05.027_bib0150) 2020; 82 Paller (10.1016/j.ad.2021.05.027_bib0175) 2020; 183 Paller (10.1016/j.ad.2021.05.027_bib0155) 2016; 74 Philipp (10.1016/j.ad.2021.05.027_bib0165) 2020; 183 10.1016/j.ad.2021.05.027_bib0180 Ollech (10.1016/j.ad.2021.05.027_bib0120) 2019; 30 Kaushik (10.1016/j.ad.2021.05.027_bib0105) 2019; 80 Bronckers (10.1016/j.ad.2021.05.027_bib0140) 2017; 153 Klufas (10.1016/j.ad.2021.05.027_bib0195) 2016; 33 |
| References_xml | – volume: 35 start-page: 938 year: 2021 end-page: 947 ident: bib0170 article-title: Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial publication-title: J Eur Acad Dermatol Venereol – volume: 390 start-page: 40 year: 2017 end-page: 49 ident: bib0160 article-title: Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial publication-title: Lancet – volume: 30 start-page: 152 year: 2019 end-page: 155 ident: bib0120 article-title: Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center publication-title: J Dermatolog Treat – volume: 14 start-page: 881 year: 2015 end-page: 886 ident: bib0185 article-title: Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review publication-title: J Drugs Dermatol – volume: 102 start-page: 132 year: 2011 end-page: 141 ident: bib0125 article-title: BIOBADADERM: registro español de acontecimientos adversos de terapias biológicas en Dermatología. Primer informe publication-title: Actas Dermosifiliogr – volume: 33 start-page: 142 year: 2016 end-page: 149 ident: bib0195 article-title: Treatment of moderate to severe pediatric psoriasis: a retrospective case series publication-title: Pediatr Dermatol – volume: 183 start-page: 664 year: 2020 end-page: 672 ident: bib0165 article-title: Ustekinumab for the treatment of moderate to severe plaque psoriasis in paediatric patients (≥6 to ≤12 years of age): efficacy, safety, pharmakokinetic and biomarker results from the open-label CADMUS Jr study publication-title: Br J Dermatol – volume: 74 start-page: 280 year: 2016 end-page: 287 ident: bib0155 article-title: Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis publication-title: J Am Acad Dermatol – volume: 174 start-page: 1118 year: 2015 end-page: 1121 ident: bib0190 article-title: Systemic treatments in childhood psoriasis: a French multicentre study on 154 children publication-title: Br J Dermatol – volume: 82 start-page: 161 year: 2020 end-page: 201 ident: bib0110 article-title: Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients publication-title: J Am Acad Dermatol – volume: 111 start-page: 752 year: 2020 end-page: 760 ident: bib0130 article-title: Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años Datos obtenidos del registro español Biobadaderm publication-title: Actas Dermosifiliogr – reference: [accessed 7.2.21]. – volume: 106 start-page: 257 year: 2020 end-page: 260 ident: bib0135 article-title: Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis in pediatric patients publication-title: Cutis – volume: 27 start-page: 395 year: 2016 end-page: 398 ident: bib0145 article-title: Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis publication-title: J Dermatol Treat – reference: European Medicines Agency. Available from: – volume: 153 start-page: 1147 year: 2017 end-page: 1157 ident: bib0140 article-title: Safety of systemic agents for the treatment of pediatric psoriasis publication-title: JAMA Dermatol – volume: 82 start-page: 389 year: 2020 end-page: 397 ident: bib0150 article-title: Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study publication-title: J Am Acad Dermatol – volume: 84 start-page: 432 year: 2021 end-page: 470 ident: bib0115 article-title: Joint AAD-NPF Guidelines for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures publication-title: J Am Acad Dermatol – volume: 183 start-page: 231 year: 2020 end-page: 241 ident: bib0175 article-title: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) publication-title: Br J Dermatol – volume: 80 start-page: 43 year: 2019 end-page: 53 ident: bib0105 article-title: Psoriasis: which therapy for which patient: Focus on special populations and chronic infections publication-title: J Am Acad Dermatol – volume: 109 start-page: 722 year: 2018 end-page: 732 ident: bib0200 article-title: Tratamiento sistémico de la psoriasis moderada-grave en edad pediátrica en Galicia: estudio descriptivo publication-title: Actas Dermosifiliogr – volume: 84 start-page: 432 year: 2021 ident: 10.1016/j.ad.2021.05.027_bib0115 article-title: Joint AAD-NPF Guidelines for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2020.07.087 – volume: 33 start-page: 142 year: 2016 ident: 10.1016/j.ad.2021.05.027_bib0195 article-title: Treatment of moderate to severe pediatric psoriasis: a retrospective case series publication-title: Pediatr Dermatol doi: 10.1111/pde.12782 – volume: 183 start-page: 231 year: 2020 ident: 10.1016/j.ad.2021.05.027_bib0175 article-title: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) publication-title: Br J Dermatol doi: 10.1111/bjd.19147 – volume: 390 start-page: 40 year: 2017 ident: 10.1016/j.ad.2021.05.027_bib0160 article-title: Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(17)31189-3 – volume: 174 start-page: 1118 year: 2015 ident: 10.1016/j.ad.2021.05.027_bib0190 article-title: Systemic treatments in childhood psoriasis: a French multicentre study on 154 children publication-title: Br J Dermatol doi: 10.1111/bjd.14326 – volume: 109 start-page: 722 year: 2018 ident: 10.1016/j.ad.2021.05.027_bib0200 article-title: Tratamiento sistémico de la psoriasis moderada-grave en edad pediátrica en Galicia: estudio descriptivo publication-title: Actas Dermosifiliogr doi: 10.1016/j.ad.2018.05.003 – volume: 82 start-page: 161 year: 2020 ident: 10.1016/j.ad.2021.05.027_bib0110 article-title: Joint American Academy of Dermatology – National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2019.08.049 – volume: 153 start-page: 1147 year: 2017 ident: 10.1016/j.ad.2021.05.027_bib0140 article-title: Safety of systemic agents for the treatment of pediatric psoriasis publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2017.3029 – volume: 27 start-page: 395 year: 2016 ident: 10.1016/j.ad.2021.05.027_bib0145 article-title: Effectiveness and safety of cyclosporine in pediatric plaque psoriasis: a multicentric retrospective analysis publication-title: J Dermatol Treat doi: 10.3109/09546634.2015.1120852 – volume: 35 start-page: 938 year: 2021 ident: 10.1016/j.ad.2021.05.027_bib0170 article-title: Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomised, controlled trial publication-title: J Eur Acad Dermatol Venereol doi: 10.1111/jdv.17002 – volume: 82 start-page: 389 year: 2020 ident: 10.1016/j.ad.2021.05.027_bib0150 article-title: Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: results from a phase 2 open-label study publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2019.08.019 – volume: 74 start-page: 280 year: 2016 ident: 10.1016/j.ad.2021.05.027_bib0155 article-title: Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2015.09.056 – ident: 10.1016/j.ad.2021.05.027_bib0180 – volume: 14 start-page: 881 year: 2015 ident: 10.1016/j.ad.2021.05.027_bib0185 article-title: Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review publication-title: J Drugs Dermatol – volume: 111 start-page: 752 year: 2020 ident: 10.1016/j.ad.2021.05.027_bib0130 article-title: Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años Datos obtenidos del registro español Biobadaderm publication-title: Actas Dermosifiliogr doi: 10.1016/j.ad.2020.05.008 – volume: 106 start-page: 257 year: 2020 ident: 10.1016/j.ad.2021.05.027_bib0135 article-title: Translating the 2019 AAD-NPF guidelines of care for the management of psoriasis in pediatric patients publication-title: Cutis doi: 10.12788/cutis.0115 – volume: 102 start-page: 132 year: 2011 ident: 10.1016/j.ad.2021.05.027_bib0125 article-title: BIOBADADERM: registro español de acontecimientos adversos de terapias biológicas en Dermatología. Primer informe publication-title: Actas Dermosifiliogr doi: 10.1016/j.ad.2010.10.016 – volume: 30 start-page: 152 year: 2019 ident: 10.1016/j.ad.2021.05.027_bib0120 article-title: Biologic treatment of recalcitrant pediatric psoriasis: a case series from a tertiary medical center publication-title: J Dermatolog Treat doi: 10.1080/09546634.2018.1476655 – volume: 183 start-page: 664 year: 2020 ident: 10.1016/j.ad.2021.05.027_bib0165 article-title: Ustekinumab for the treatment of moderate to severe plaque psoriasis in paediatric patients (≥6 to ≤12 years of age): efficacy, safety, pharmakokinetic and biomarker results from the open-label CADMUS Jr study publication-title: Br J Dermatol doi: 10.1111/bjd.19018 – volume: 80 start-page: 43 year: 2019 ident: 10.1016/j.ad.2021.05.027_bib0105 article-title: Psoriasis: which therapy for which patient: Focus on special populations and chronic infections publication-title: J Am Acad Dermatol doi: 10.1016/j.jaad.2018.06.056 |
| SSID | ssj0025306 ssj0001213531 |
| Score | 2.2549553 |
| Snippet | [Display omitted]
Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment.... Graphical abstract Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this... |
| SourceID | doaj pubmed crossref elsevier |
| SourceType | Open Website Index Database Enrichment Source Publisher |
| StartPage | T401 |
| SubjectTerms | BIOBADADERM Childhood Dermatology Infancia Psoriasis Registries Registros |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gLgvK1QJEPXDhEdT4c29y6haogLVQtlSohZNme2WpRlUVk4fd37DhhD1V74RrFTjIzzryRx-8x9rbVBkqllgUG4YomhKrwwZeFBi8aMIRJk2bk4kt7fN58vpAXW1JfsSdsoAceDLfvpNfQxqyEovEStAahvZYCKqUDYPz7CiPGYiqXWrJOqpoRwRSKEEzeoBw6u1xkCK3KxNgZ1WS2ElLi7b8pL20lnaNH7GFGi_xgeMvH7B52u-z-Iu-HP2F_v6dcc0WAEXj-lh886ZvRJb5Z8zOkWEV-0q8p0vpVz1cdn-Q5uOuAp_XOTwZ-1f49p8Dh809f5wcfyEmnC36Kl0kRjv9jRX7Kzo8-fjs8LrKSQhEaaTYFAlAeAsI6ZU2QAZYu1EutgjetXmqMAjxlQJDGQ-0kBOWdDmjIvNIYqHz9jO106w5fMA4NEiqLpMyKajGlPba-jVVm5QzSfDO2P5rThkwzHtUuruzYT_bTOrDRAVZISw6YsXfTiF8DxcYt986jh6b7Ijl2ukAhY7OZ7V0hM2Pl6F87nj-lPyZNtLrlweqmMdjnJd_b0vaVFfYsURDVsZCOUFyVM1ZPIzOqGdDKHc97PgTe9Km1bBQVd_rl_zDBK_agiuc4UgvSa7az-f0H9whdbfybtJCuASeRHn0 priority: 102 providerName: Directory of Open Access Journals |
| Title | [Translated article] Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0001731022002071 https://www.clinicalkey.es/playcontent/1-s2.0-S0001731022002071 https://dx.doi.org/10.1016/j.ad.2021.05.027 https://www.ncbi.nlm.nih.gov/pubmed/35477588 https://doaj.org/article/a5b8d61293e04b5d88d08b850d278cde |
| Volume | 113 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdGJyFeEONrBVb5gRceQvPlxOGtHZs6qo6pMDEJISv2uVPQlE5L4ZG_nTvHyYaYhsRTJMt2Yt_Zdxf7fj_GXmeygCjPV4E1YRmkxsSBNjoKJOgwhQJ9UscZuTjOZqfphzNxtsX2u1wYulbp9_52T3e7tS8Z-9kcX1YV5fiiNiUUsZDPQ3nk2zFaezlg25Oj-ey4j7tE4ig2qX5ADfxpZXvNqyS40Dhy8J1ELXPDOjkQ_9uM1A0LdPiIPfSuI5-0X7fDtmz9mN1f-MPxJ-znV2d4LtB7BO7H8I07sjMs4ps1_2RRcS0_adaodk3V8KrmPVcHL2vgbvHzkxZstXnHUYv49OjjdPIeJbZc8KU9d_Rw_Boi-Sk7PTz4vD8LPK1CYFJRbAILgEYJ0PGJEvQfYFWaZCVzo4tMrqQlNp4IZ18UGpJSgMl1KY0tDFhRFBDr5Bkb1Ova7jIOqUUXjRCacwzMcqltpjMKOeOysNjfkI276VTGY44T9cWF6i6XfVclKBKACoVCAQzZm77FZYu3cUfdKUmor0dI2a5gfXWu_DSrUmgJGXk1Nky1ACkhlFqKEOJc4piGLOrkq7pkVNw-saPqjhfnt7WxjV__jYpUE6tQ_aWjQ5b0Lf9Q83-873mreP1QE5HmGOnJF__V30v2IKYsDncB6RUbbK5-2D30rTZ6xO69_RWN_Aqi53z5ZT5yfyp-Ax_aIpc |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELemTgJeEONrZQP8wAsPUfPlxNlbOza1bC3T2KRJCFmxz52CpnRaCn__7hwnDDENiVfLduK7s-9O9v1-jH3IZAFRni8Da8IySI2JA210FEjQYQoFxqSOM3K-yKbn6ecLcbHB9rtaGHpW6c_-9kx3p7VvGXlpjq6rimp80ZoSylgo5qE68s2USK0HbHM8O5ou-rxLJI5ik_oHNMDfVrbPvEqCC40jB99J1DJ3vJMD8b_PSd3xQIfP2FMfOvJx-3dbbMPWz9mjub8cf8F-fXOO5wqjR-B-Dd-5IzvDJr5e8a8WDdfyk2aFZtdUDa9q3nN18LIG7jY_P2nBVps9jlbEJ7Mvk_En1NjpnJ_aS0cPx39DJL9k54cHZ_vTwNMqBCYVxTqwAOiUAAOfKMH4AZalSZYyN7rI5FJaYuOJUPqi0JCUAkyuS2lsYcCKooBYJ6_YoF7VdptxSC2GaITQnGNilkttM51RyhmXhcX5hmzUiVMZjzlO1BdXqntc9kOVoEgBKhQKFTBkH_sR1y3exgN9J6Shvh8hZbuG1c2l8mJWpdASMopqbJhqAVJCKLUUIcS5xDUNWdTpV3XFqHh84kTVAx_O7xtjG7__GxWpJlah-stGhyzpR_5h5v_43uvW8PqlJiLNMdOTb_5rvvfs8fRsfqyOZ4ujHfYkpooO9xhplw3WNz_tW4yz1vqd30e3E1Qh5Q |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%5BTranslated+article%5D+Moderate+to+Severe+Psoriasis+in+Pediatric+and+Young+Patients%3A+The+BIOBADADERM+Registry+Experience&rft.jtitle=Actas+dermo-sifiliogr%C3%A1ficas&rft.au=Nieto+Benito%2C+L.M.&rft.au=Carretero%2C+G.&rft.au=Rivera-D%C3%ADaz%2C+R.&rft.au=Carrascosa%2C+J.M.&rft.date=2022-04-01&rft.pub=Elsevier+Espa%C3%B1a%2C+S.L.U&rft.issn=0001-7310&rft.volume=113&rft.issue=4&rft.spage=T401&rft.epage=T406&rft_id=info:doi/10.1016%2Fj.ad.2021.05.027&rft.externalDocID=S0001731022002071 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00017310%2FS0001731022X00057%2Fcov150h.gif |